None
Quote | CSPC Pharmaceutical Group Ltd ADR (OTCMKTS:CSPCY)
Last: | $2.90 |
---|---|
Change Percent: | 0.0% |
Open: | $2.898 |
Close: | $2.90 |
High: | $2.9197 |
Low: | $2.89 |
Volume: | 25,965 |
Last Trade Date Time: | 04/17/2024 03:00:00 am |
News | CSPC Pharmaceutical Group Ltd ADR (OTCMKTS:CSPCY)
2024-01-29 09:00:03 ET More on Corbus Pharmaceuticals Corbus Pharma surges after early Phase 1 data for tumor candidate Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals Historical earnings data for Corbus Pharmaceuticals Financial information for...
2024-01-26 13:34:16 ET More on Corbus Pharmaceuticals Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals Historical earnings data for Corbus Pharmaceuticals Financial information for Corbus Pharmaceuticals Read the full article on Seeking Alpha ...
Message Board Posts | CSPC Pharmaceutical Group Ltd ADR (OTCMKTS:CSPCY)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
CSPC Pharmaceutical Group Ltd ADR Company Name:
CSPCY Stock Symbol:
OTCMKTS Market:
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refract...
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire NEW YORK , April 26, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology comp...
Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC) PR Newswire CRB-701 (SYS6002) is designed for improved therapeutic index and to act on a broad range of Nectin-4 expressing tumors ...